PND31 Assessing the Relationship Between the Number of Nursing Support Encounters and Medication Possession Ratio in Relapsing Remitting Multiple Sclerosis Patients Receiving Glatiramer Acetate  by Jones, J. et al.
PND27
MODEL OF RASAGILINE VERSUS STANDARD OF CARE FOR PARKINSON’S
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OBJECTIVES: To incorporate the rasagiline effects observed in the ADAGIO trial
into a 25-year Parkinson’s Disease (PD) progression model. A model evaluating
economic gains from slowing progression was previously developed but progres-
sion reduction effects had been hypothetical; including rasagiline effects would be
informative. METHODS: A disease progression model based on 10 cohort studies
containing 3318 patients was used to assess the expected time to progression
through Hoehn and Yahr (H&Y) stages one to 5 for those untreated with rasagiline.
ADAGIO’s relative difference in the Activities of Daily Living-Unified Parkinson’s
Disease Rating Scale (ADL-UPDRS) from week 0 to 36 for placebo vs. rasagiline (1
mg/day) were used to parameterize the reduction in progression rate for rasagiline.
Relative differences in total UPDRS changewere also evaluated. Effects observed in
the clinical trials were assumed to persist over the course of the model. Medicare
claims data for 25,577 patients over 9 years were used to parameterize direct med-
ical costs by H&Y stage. Patients were age 62, 61% male, and 50% H&Y1/50% H&Y2
at baseline. Costs and life-years were discounted at 3%. RESULTS: Based on the
relative rate of change in ADL-UPDRS, rasagiline reduced progression rates by
76.1%. Rasagiline added $48,226 in drug costs over 25 years. Total direct costs
(medical and pharmacy) for untreated patients were $264,389 and $148,736 for
rasagiline treated patients; incremental direct costs were $115,653 in favor of rasa-
giline. Incremental life years gainedwere 1.97 in favor of rasagiline. At 10 years, the
model associated rasagiline with a 45% reduction in patients who were in H&Y3,
H&Y4 or H&Y5. Sensitivity analysis indicated that incremental costs varied be-
tween $31,146 and $130,888. CONCLUSIONS: Clinical trials results for rasagiline (1
mg/day) indicated that the change in relative progression rate versus placebo could
yield substantial economic and clinical benefits over a 25 year horizon.
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OBJECTIVES:Themobility impairment associatedwithmultiple sclerosis (MS)may
have an impact on employment status, work productivity, indirect costs, and
health-related quality of life (HRQoL).We estimated indirect costs and HRQoL (util-
ities) of MS patients in the United States (US). METHODS: The North American
Committee on Multiple Sclerosis (NARCOMS) registry was used to conduct a cross-
sectional study of participants who completed the biannual update and supple-
mental Spring 2010 surveys. Demographic, employment status, income, mobility
impairment, and health utility data were collected from registry participants who
agreed to participate in the Mobility Study. Mean annual indirect costs per partic-
ipant in 2011 USD and mean utilities for the population and for cohorts reporting
different levels of mobility impairment were estimated. The Patient Determined
Disease Steps, NARCOM’s mobility Performance Scale score, and question 1 of the
12-item Multiple Sclerosis Walking Scale were used to define levels of mobility
impairment. Indirect costs were estimated using the human capital approach and
utilities using the EuroQol 5-Dimension. RESULTS: Analyses included 3433 to 3616
participants, depending on survey completeness. Most participants were women
(80.1%),40 years of age (80.7%), and had MS for10 years (84.9%). A total of 20.3%
of participants experienced a relapse in the past 6months and 40.4%were receiving
a disease-modifying drug; 32%were notworking or attending school. Total indirect
costs per participant per year were estimated to be $21,68020,730. The largest
relative increases in indirect costs occurred at earlier impairment stages, regard-
less of the mobility impairment measure used. Participants’ mean utility score
(0.730.18) was lower than that of a similarly aged sample from the general US
population (0.87). As with indirect costs, the largest declines in utility were seen at
earliermobility impairment stages.CONCLUSIONS:Mobility impairmentmay con-
tribute to increases in indirect costs and declines in HRQoL in MS patients.
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OBJECTIVES: To assess the nature and extent of burden experienced by caregivers
of patients with Fragile X Syndrome (FXS) in the United States (US). METHODS: A
total of 351 caregivers enrolled in a FXS survey research registry completed a web-
based (93%) or phone-based (7%) survey that captured information on health care
utilization, financial burden, employment status, paid and unpaid caregiver hours,
and caregiver injuries and mental health. RESULTS: Respondents (293 with male
child; 58 with female) were mostly female (91%), Caucasian (92%), and married
(84%) with an average age of 50 years. Caregivers reported low hospitalization rates
(2%) and Emergency Department visits (6%) over the past 12 months. The most
commonly seen specialists were ophthalmologists (33%), psychiatrists (33%), de-
velopmental-behavioral pediatricians (28%), and neurologists (22%). 40% of males
and 22% of females needed at least one of 11 common medical tests/procedures
(e.g. CT scan, X-Ray). Nearly 19% of patients needed general anesthesia/sedation
for a dental procedure. 66% were on at least one prescription medication for prob-
lems related to FXS. On average, parents spent nearly 9 hours/day caring for their
child. They also obtained 5 hours of paid support/day. During the past 30 days, the
average caregiver and their spouse took 19 hours off from work to care for their
child. More than 35% reported that someone in their family had quit working, 28%
turned down a job or promotion, 54% changed work hours, and 26% changed jobs.
Nearly 29% reported being injured by their child with FXS (16 injuries per year by
male children; 4 injuries per year by female children). 35% of caregivers reported
seeking treatment for depression or anxiety, and 28% took prescription medica-
tions to treat these symptoms. CONCLUSIONS: Caring for a child with FXS is asso-
ciated with substantial caregiver burden and increased health care utilization.
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OBJECTIVES: To evaluate health care resource utilization (HRU) and health-related
quality of life (HRQOL) between United Kingdom (UK) Neurogenic Detrusor Over-
activity (NDO) patients with and without adequate response to anticholinergics.
METHODS: A retrospective database analysis was conducted using the Adelphi
OABDisease Specific Programme, amulti-national, cross-sectional survey reported
from both patients’ and physicians’ perspectives. The population for this analysis
was limited to UK NDO patients with OABwith or without incontinence, excluding
those with stress incontinence. Inadequate response to anticholinergics was de-
fined by switching anticholinergics due to lack of efficacy or tolerability. HRU indi-
cators included: 1) paid employment; 2) OAB-related hospitalization in the past 12
months; 3) ever having undergone OAB-related surgery; and 4) number of physi-
cian visits due to their bladder condition in the past three months. HRQOL was
measured by the Incontinence Quality of Life Questionnaire (I-QOL) total score.
Statistical differences were tested using Fisher’s exact test for dichotomous out-
comes and Wilcoxon rank-sum test for continuous outcomes. RESULTS: The UK
sample of patients with OAB or urinary incontinence was 1304 patients recruited
by 122 physicians. A total of 40 NDO patients who filled out a self-completion
questionnaire were identified, of whom 24 (60%) had inadequate response to anti-
cholinergics. A significantly higher proportion of patients with inadequate re-
sponse to anticholinergics underwent OAB-related surgeries (N(%): 11(46%) vs.
0(0%), p0.01) versus patients with adequate response. In addition, patients with
inadequate response had significantly more physician visits (mean(SD): 3.6(2.7) vs.
1.7(1.6), p0.03) and a statistically and clinically lower I-QOL total score (mean(SD):
49(18) vs. 72(23), p0.01). The proportion of patients on paid employment or have
had OAB-related hospitalization did not significantly differ between the groups.
CONCLUSIONS: Patients with inadequate response to anticholinergics were more
likely to have greater health resource utilization and lower quality of life compared
with patients with adequate response.
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REMITTING MULTIPLE SCLEROSIS PATIENTS RECEIVING GLATIRAMER
ACETATE
Jones J, Scheidt D, Kaushal R, Carroll CA
Teva Pharmaceuticals, Kansas City, MO, USA
OBJECTIVES:To evaluate the relationship between the numbers of patient encoun-
ters over a two year period and medication possession ratio (MPR) in patients
receiving services through a voluntary support program sponsored by the manu-
facturer of Glatiramer Acetate. METHODS: De-identified patient records were de-
rived from a decision support system used for normal business operations. Patient
recordswere included in the evaluation if theywere 1) continuously enrolled in the
program for aminimum of 24months, and 2) received Glatiramer Acetate. Patients
were grouped into four cohorts based upon the average number of encounterswith
the support services over the two year enrollment period. Chi-squared statistics
were used to assess variation in categorical variable and Analysis of Variance
(ANOVA) compared mean values for continuous variables. RESULTS: A total of
10,989 patients were continuously enrolled in the support program between the
dates of September 2002 and August 2011. The mean age of the study population
was 45 years with no difference in mean age observed across the four cohorts (p
0.09). The mean MPR for the study population was 0.85. Patients utilizing the sup-
port services once or twice during the two year study period had a lower MPR (0.84)
than patients who utilized the services more frequently (0.87). CONCLUSIONS:
Data from retail and specialty pharmacy services included within the Invision
DataMart™ estimates a MPR for Glatiramer Acetate of 0.76 to 0.80. Nursing support
services for multiple sclerosis enhance patient adherence by up to about 15% over
that observed through retail or specialty pharmacy services alone. Costs of such
service accrue to the sponsor while the benefit of improved compliance (i.e. lower
medical expenditures) accrues to payers.
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